During the past few decades, many of the synthetic chemicals are able to produce nanoparticles and nanoclusters, although these chemicals primarily act as reducing and capping agents, they are very toxic and hazardous and make the nanoparticles biologically incompatible. Thus there is need for green chemistry that includes a clean, non-toxic and environmental friendly method of nanoparticles synthesis. Cobalt, iron and copper nanoparticles were synthesized using the stem-bark extract of khayasenegalensis (mahogany) where cobalt chloride (CoCl₂ 6H₂O), ferric chloride (FeCl₂), and copper sulphate (CuSO₄ H₂O) were used as the metal precursor respectively. The change in color from light brown to dark brown indicates the formation of cobalt nanoparticles, from light brown to dark green indicates the formation of copper nanoparticles and also the change in color from light brown to a dark color indicates formation of iron nanoparticles. The nanoparticles were further characterized using UV visible spectroscopy, FTIR, and SEM. The UV result for CoNPs showed the highest peak at 500nm and both FeNPs and CuNPs showed the highest peak at 300nm. The FTIR results for all the nanoparticles showed the presence of Alkaloids and triterpenes. Also the SEM result showed spherical granular, partially dispersed and monodispersed morphology for CoNPs, FeNPs and CuNPs respectively. Moreover, the antibacterial activity of the synthesized NPs when tested against two gram positive bacteria and two gram negative bacteria was evaluated and good results were obtained. The antifungal activity when tested against two fungi showed a very good result.

The synthesis and optimization of Active Pharmaceutical Ingredients (APIs) is fundamental to pharmaceutical drug development, directly influencing drug efficacy, safety, and cost-effectiveness. Over recent years, significant advancements in synthetic methodologies and manufacturing technologies have transformed API production. This manuscript provides an overview of the latest innovations in API synthesis, focusing on key techniques such as green chemistry, continuous flow chemistry, biocatalysis, and automation. Green chemistry principles, including solvent substitution and catalytic reactions, have enhanced sustainability by reducing waste and energy consumption. Continuous flow chemistry offers improved reaction control, scalability, and safety, while biocatalysis provides an eco-friendly alternative for synthesizing complex and chiral APIs. Additionally, the integration of automation and advanced process control using machine learning and real-time monitoring has optimized production efficiency and consistency. The manuscript also discusses the challenges associated with regulatory compliance and quality assurance, highlighting the role of advanced analytical techniques such as HPLC, NMR, and mass spectrometry in ensuring API purity. Looking ahead, personalized medicine and smart manufacturing technologies, including blockchain for traceability, are expected to drive further innovation in API production. This review concludes by emphasizing the need for continued advancements in sustainability, efficiency, and scalability to meet the evolving demands of the pharmaceutical industry, ultimately enabling the development of safer, more effective, and environmentally responsible medicines.

Active Pharmaceutical Ingredients (APIs) form the backbone of pharmaceutical formulations, influencing their efficacy, safety, and stability. Essence control of APIs involves stringent regulation and optimization of their chemical, physical, and biological properties to ensure consistent quality and therapeutic outcomes. This manuscript explores the critical aspects of essence control in APIs, including synthesis, characterization, quality assessment, and regulatory considerations. The synthesis of Active Pharmaceutical Ingredients is a pivotal stage in pharmaceutical manufacturing, where precise control over chemical reactions and process conditions is paramount to achieving high-quality, safe, and effective medicines. Advances in synthetic methodologies, optimization strategies, sustainability practices, and the implementation of PAT technologies continue to drive innovation in API synthesis, supporting the development of novel therapeutic agents and enhancing pharmaceutical manufacturing efficiency.